Evocatal moves to new HQ near Cologne

By Gareth Macdonald

- Last updated on GMT

Evocatal moves to new HQ near Cologne
Evocatal moves to new HQ near Cologne
Lanxess backed enzyme and fine chemicals producer evocatal has moved to a new HQ, beefed up production capacity and is on the look out for new scientific staff.

The new base in the city of Monheim, between Cologne and Dusseldorf, has twice the laboratory and production space of evocatal's former headquarters in Dusseldorf.

The new site houses new 100L industrial fermenters to support the manufacture of biocatalysts in process-relevant quantities.

Evocatal told us that: "It’s a typical 150 L pilot-scale batch fermenter with 100 L working volume. The fermenter will be run in a multipurpose mode, both run pilot process for scale up as well as some in-house productions for own products.

"With our new multipurpose equipment (20 l volume) evocatal will be able to produce chemicals up to multi-kg scale

Fundraising

The relocation to the new HQ was funded with the proceeds of a EUR3.5m ($4.7m) series B fund raising round evocatal completed in June.

The firm attracted investment from existing backers Roland Oetker, High-Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner and new investors Nrw.Bank.

Cologne-based fine chemicals giant Lanxess also backed evocatal's fundraising round building on the relationship the firms established in 2012 when they teamed up to develop biotechnological methods for the synthesis of precursors for the rubber production.

Evocatal told us that: "The fresh funding is being used to implement the Company’s growth strategy including the relocation and expansion of facilities. Thus evocatal now can accomodate additional staff, and we have been and will be hiring new technical and research personnel over the year. We are looking for scientist with interdisciplinary skills in both chemistry and biotechnology.

"This month evocatal is looking for an Analytical Chemist to strengthen our quality control and quality management team."

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars